Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) EBITDA (2017 - 2024)

Solid Biosciences' EBITDA history spans 8 years, with the latest figure at -$39.9 million for Q4 2024.

  • For Q4 2024, EBITDA fell 79.19% year-over-year to -$39.9 million; the TTM value through Dec 2024 reached -$129.7 million, down 24.44%, while the annual FY2024 figure was -$129.7 million, 24.44% down from the prior year.
  • EBITDA for Q4 2024 was -$39.9 million at Solid Biosciences, down from -$35.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$16.9 million in Q1 2021 and bottomed at -$39.9 million in Q4 2024.
  • The 5-year median for EBITDA is -$24.2 million (2022), against an average of -$25.1 million.
  • The largest annual shift saw EBITDA skyrocketed 37.13% in 2021 before it crashed 85.32% in 2022.
  • A 5-year view of EBITDA shows it stood at -$21.3 million in 2020, then grew by 12.62% to -$18.7 million in 2021, then plummeted by 85.32% to -$34.6 million in 2022, then soared by 35.59% to -$22.3 million in 2023, then tumbled by 79.19% to -$39.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's EBITDA are -$39.9 million (Q4 2024), -$35.2 million (Q3 2024), and -$27.8 million (Q2 2024).